Good
Mostly Aligned
Patient Risk:
Low
Summary
Most extracted claims are directly supported by the provided label sections (indications and class/mechanism description). The claim about FDA approval occurring in 2017 is not supported by the supplied label text.
Category Scores
Accurate Statements
Rhopressa (netarsudil) is an ophthalmic drug.
11 DESCRIPTION (RHOPRESSA (netarsudil ophthalmic solution) 0.02%...)
Rhopressa (netarsudil) is used to lower intraocular pressure in people with glaucoma or ocular hypertension.
1 INDICATIONS AND USAGE (reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension)
Netarsudil (Rhopressa) is a member of the Rho kinase inhibitor class.
11 DESCRIPTION (Netarsudil is a Rho kinase inhibitor.)
Unsupported Statements
Rhopressa (netarsudil) received FDA approval in 2017 for lowering intraocular pressure in people with glaucoma or ocular hypertension.
The provided label sections do not state an FDA approval year; no label text supports '2017'.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The only unsupported claim concerns the FDA approval year and does not, by itself, introduce an indicated use, dosing, contraindication, or safety instruction conflict based on the provided label text.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Remove or qualify the 'FDA approval in 2017' statement because it is not supported by the supplied label text.
Suggested Improvement
State only what the label supports (indication and Rho kinase inhibitor class) without asserting an approval year not present in the provided label sections.